Harbour BioMed and Fox Chase Cancer Center initiated discussions related to opening clinical trials at Fox Chase using Harbour BioMed’s candidate oncology agents. Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. Harbour BioMed’s current portfolio includes four clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.
About Our Agreement
Confidentiality Agreement - details are confidential and cannot be disclosed to the public.
